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Abstract
Virus-infected cells secrete a broad range of interferon (IFN) subtypes which in turn trigger the synthesis of antiviral factors
that confer host resistance. IFN-a, IFN-b and other type I IFNs signal through a common universally expressed cell surface
receptor, whereas IFN-l uses a distinct receptor complex for signaling that is not present on all cell types. Since type I IFN
receptor-deficient mice (IFNAR1
0/0) exhibit greatly increased susceptibility to various viral diseases, it remained unclear to
which degree IFN-l might contribute to innate immunity. To address this issue we performed influenza A virus infections of
mice which carry functional alleles of the influenza virus resistance gene Mx1 and which, therefore, develop a more
complete innate immune response to influenza viruses than standard laboratory mice. We demonstrate that intranasal
administration of IFN-l readily induced the antiviral factor Mx1 in mouse lungs and efficiently protected IFNAR1
0/0 mice
from lethal influenza virus infection. By contrast, intraperitoneal application of IFN-l failed to induce Mx1 in the liver of
IFNAR1
0/0 mice and did not protect against hepatotropic virus infections. Mice lacking functional IFN-l receptors were only
slightly more susceptible to influenza virus than wild-type mice. However, mice lacking functional receptors for both IFN-a/
b and IFN-l were hypersensitive and even failed to restrict usually non-pathogenic influenza virus mutants lacking the IFN-
antagonistic factor NS1. Interestingly, the double-knockout mice were not more susceptible against hepatotropic viruses
than IFNAR1
0/0 mice. From these results we conclude that IFN-l contributes to inborn resistance against viral pathogens
infecting the lung but not the liver.
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Introduction
Viral infection of vertebrate cells triggers innate immune
responses, which result in rapid synthesis of IFN and other pro-
inflammatory cytokines [1–4]. Virus-induced IFN represents a
complex mixture of IFN subtypes which act on target cells by
engaging two distinct cell surface receptors [5]. All members of the
type I IFN family which, in the mouse, includes 14 different IFN-a
subtypes, IFN-b, IFN-k, IFN-e and limitin, use the same
heterodimeric IFN-a/b receptor complex (IFNAR1/2) for signal-
ing [6]. By contrast, signaling by type III IFN family members (in
the mouse IFN-l2 and IFN-l3) occurs through the heterodimeric
interleukin-28 receptor a/interleukin-10 receptor b (IL-28Ra/IL-
10Rb) complex [7,8]. Although activating distinct receptor
systems, IFN-l and type I IFNs trigger strikingly similar responses
in target cells which mostly result from phosphorylation-induced
activation of transcription factors STAT-1 and STAT-2 [9,10].
The IFNAR1/2 complex is present on most if not all nucleated
cells, whereas expression of the IL-28Ra subunit seems to be cell
type-restricted [11,12]. Consequently, antiviral protection by type
I IFN is observed in most cell types, whereas antiviral protection
mediated by IFN-l is restricted to cells that express functional IL-
28R complexes. The spectrum of cell types that respond to IFN-l
in vivo is poorly defined. Recent experiments suggested that
epithelial cells are the main targets of IFN-l in the mouse [13].
Information on the contribution of IFN-l to virus resistance at
the level of the whole organism is very limited as mice lacking
functional IFN-l receptors (IL28Ra
0/0) were generated only
recently [14]. Unlike knockout mice lacking functional type I
IFN receptors (IFNAR1
0/0) that are highly susceptible to a broad
spectrum of different viruses [15], IL28Ra
0/0 and wild-type mice
did not differ significantly in resistance to a large panel of
pathogenic viruses [14]. The only observed difference between
wild-type and IL28Ra
0/0 mice was that treatment of knockout
mice with toll-like receptor (TLR) 3 and TLR9 agonists failed to
induce resistance to vaginal infection with herpes simplex virus
type 2 [14].
Here we used Mx1
+/+ mice to investigate the relative
contributions of IFN-l and type I IFN in immunity toward
influenza A virus. Mx1
+/+ mice differ from standard mouse strains
in being fully IFN-competent. They carry functional alleles of the
influenza virus resistance gene Mx1, which is defective in standard
laboratory mice [16]. Consequently, in Mx1
+/+ mice, virus-
induced IFN activates the Mx1 gene in addition to other antiviral
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more robust resistance to influenza and influenza-like viruses
[17,18]. The Mx1
+/+ mouse model system has the power to reveal
even subtle defects in antiviral immunity against orthomyxovirus-
es. It has recently been used to uncover the beneficial effect of
IFN-b in influenza virus defense [19]. It was further used to
demonstrate that IFN-a might be used to prevent disease induced
by highly lethal human H5N1 influenza viruses [17]. Using this
experimental system we now demonstrate that IFN-l contributes
to innate immunity against influenza virus but not against two
different hepatotropic viruses. These differences in virus suscep-
tibility correlated with the differing ability of virus-induced IFN-l
to activate the Mx1 gene in lung and liver of IFNAR1
0/0 mice.
Results
IFN-l is induced in virus-infected lung and liver of
IFNAR1
0/0 mice
Since virus-induced activation of IFN genes requires positive
feedback through the IFN-a/b receptor in certain cell types [20],
we first determined whether the major IFN subtypes are induced
in lung and liver of IFNAR1
0/0 mice after infection with viruses
that strongly activate the innate immune system. As can be seen in
Figure 1, we observed strong transcriptional activation of genes for
the IFN-a family, IFN-b and IFN-l2 in the lung of mice infected
intranasally with the influenza A virus mutants SC35M-DNS1 and
PR8-DNS1 that are known to induce large amounts of type I IFN
[21,22]. Similarly, strong transcriptional activation of IFN-a, IFN-
b and IFN-l genes was observed in the liver of IFNAR1
0/0 mice
infected with a mutant of hepatotropic Thogotovirus (THOV) that
lacks the IFN-antagonistic factor ML (THOV-DML) [23].
Exogenous IFN-l protects IFNAR1
0/0 mice against
intranasal challenge with influenza A virus but not
against intraperitoneal challenge with Thogotovirus
In a first experiment, IFNAR1
0/0 mice were treated with
exogenous IFN-l by the intranasal route to determine whether
this cytokine might contribute to protection from pneumonia
inducedbypathogenicinfluenzaviruses.GroupsofIFNAR1
0/0mice
were treated with 7,500 units of either recombinant IFN-l2 or IFN-
l3. Control animals received corresponding volumes of a mock
preparation. Ten hours later, the animals were infected with 100
plaque-forming units (pfu) (,20 LD50) of mouse-adapted H7N7
influenza A virus strain SC35M [22]. The control animals quickly
lost weight and had to be killed between days 7 and 9 post infection
due to clinical signs of pneumonia, whereas all animals treated with
eitherIFN-l2o rI F N - l3 remained healthy(Fig.2A).Sincestandard
IFNAR1
0/0 mice lacking functional Mx1 alleles developed severe
disease under identical experimental conditions inspite of treatment
with IFN-l3 (data not shown), we concluded that the protective
effect of IFN-l that we observed in our Mx1
+/+ mice was mainly
mediated by the IFN-induced resistance factor Mx1.
In a second experiment, 15,000 units of IFN-l3 were applied by
the intraperitoneal route to IFNAR1
0/0 mice carrying functional
Mx1 alleles. Ten hours later the animals were challenged with 100
pfu (,20 LD50) of THOV. Animals treated with IFN-l3 as well as
control animals treated with a mock preparation developed severe
disease between 48 and 96 hours post infection (Fig. 2B). Thus,
IFN-l exhibited effective antiviral activity in the lung, but seemed
to be inactive in the liver.
IFN-l activates Mx1 gene expression in the lung but not
liver of IFNAR1
0/0 mice
Like type I IFN, IFN-l exhibits antiviral activity by binding to a
specific cell receptor complex that can activate latent STAT
transcriptionfactors [24]. After activation, the STAT proteins move
to the nucleuswhere they activatetranscriptionof a largenumber of
IFN-responsive genes, including Mx1. To determine whether
exogenous IFN-l activates IFN-responsive genes in our IFNAR1
0/0
mice, we harvested lung and liver at 20 hours post onset of
treatment with IFN-l3 and analyzed the tissue homogenates for
Mx1 protein by western blotting. Easily detectable levels of Mx1
were present in lungs of mice that were treated intranasally with
3,500 units of IFN-l3 (Fig. 3A). The lungs of mock-treated mice did
not contain detectable levels of Mx1.
Mx1 protein could not be detected in the liver of IFNAR1
0/0 mice
treated with 15,000 units of IFN-l3 by the intraperitoneal route
(Fig. 3B). If, as a control, a cross-reactive variant of human IFN-a
Figure 1. Induction of IFN-l2 genes in virus-infected lung and
liver of IFNAR1
0/0 mice. Animals were either infected by the intranasal
route with 10
6 pfu of influenza A virus strain SC35M-DNS1 or PR8-DNS1,
or else by the intraperitoneal route with 10 pfu of hepatotropic THOV-
DML. Animals treated with plain buffer served as negative controls. At
17 hours post infection, the influenza virus-infected mice were killed
and the lungs were removed for analysis. The liver of the THOV-infected
mouse was harvested when the animal was severely diseased at
72 hours post infection. RNA samples from the organs were reverse
transcribed and analyzed by PCR for transcripts of the indicated genes.
doi:10.1371/journal.ppat.1000151.g001
Author Summary
The contribution of IFN-l to innate immunity against virus-
induced diseases has remained unclear to date as
appropriate mouse models were not available. We now
present evidence that IFN-l is involved in the antiviral
defense. Mice lacking functional IFN-l receptors were only
slightly more susceptible to influenza virus than wild-type
mice, but intranasal administration of IFN-l efficiently
protected IFN-a/b receptor-deficient mice from lethal
influenza virus infection and induced the antiviral factor
Mx1 in lungs. Mice lacking functional receptors for both
IFN-a/b and IFN-l were hypersensitive and failed to restrict
even usually non-pathogenic influenza virus mutants
lacking the IFN-antagonistic factor NS1. By contrast,
intraperitoneal application of IFN-l failed to induce Mx1
in the liver of mice and did not protect against
hepatotropic viruses. Furthermore, double-knockout mice
were not more susceptible against hepatotropic viruses
than IFN-a/b receptor-deficient mice, indicating that IFN-l
contributes to resistance against viral pathogens infecting
the lung but not the liver.
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prominently induced in the liver (Fig. 3B). To distinguish between
the possibility that liver cells lack functional receptors for IFN-l and
the possibility that the recombinant IFN-l failed to reach the liver
under our experimental conditions, we analyzed the Mx1 protein
levelsinIFNAR1
0/0miceinfected withTHOV-DMLwhichstrongly
induces IFN-l in the liver (Fig. 1). The liver of mice with severe
THOV-induced disease contained no detectable amounts of Mx1
protein (Fig. 3B). Similarly, no Mx1 protein could be detected in the
liver of terminally ill IFNAR1
0/0 mice infected with Rift Valley fever
virus clone 13 (Fig. 3B), another hepatotropic virus with strong IFN-
inducing activity [25]. Thus, differential IFN-l receptor expression
in lung and liver seemed to explain why exogenously applied IFN-l
protected IFNAR1
0/0 mice from virus-induced disease of the lung
but not the liver.
Slightly reduced resistance to influenza virus of mice
lacking functional IFN-l receptors
To directly assess the contribution of IFN-l to the protection
from influenza virus-induced lung disease, we generated IL28Ra
0/0
mice carrying functional Mx1 alleles by crossbreeding of appropri-
ate mouse strains and compared the fate of wild-type and IL28Ra
0/0
mice after challenge with 5610
4 plaque-forming units (pfu) of
SC35M. Survival of IL28Ra
0/0 mice was slightly reduced compared
to wild-type mice (Fig. 4A), but the difference was not statistically
significant. Viral titers in lungs of IL28Ra
0/0 mice were slightly but
significantly higher at 72 h post infection than in lungs of wild-type
mice (Fig. 4B).
Strongly reduced resistance to influenza virus but not to
hepatotropic viruses of IFNAR1
0/0 mice lacking functional
receptors for IFN-l
To determine the relative contributions of IFN-a/b and IFN-l in
antiviral defense we generated Mx1
+/+ mice that lack functional
receptors for both of these two classesof IFN (IFNAR1
0/0IL28Ra
0/0)
and compared them to mice that lack receptors for IFN-a/b only.
We previously demonstrated that IFNAR1
0/0 mice with intact Mx1
alleles are highly susceptible to challenge infections with wild-type
SC35M [19]. However, intranasal infection with 10
5 pfu of
SC35M-DNS1 did not induce disease in IFNAR1
0/0 mice
(Fig. 5A). Similarly, all wild-type and IL28Ra
0/0 mice remained
Figure 2. Exogenous IFN-l protects IFNAR1
0/0 mice against
intranasal challenge with influenza A virus but not against
intraperitoneal challenge with THOV. (A) Survival of mice
intranasally treated for 10 hours with a mock preparation or 7,500
units of either IFN-l2 or IFN-l3 before challenge with 100 pfu (,20
LD50) of influenza A virus strain SC35M. (B) Survival of mice
intraperitoneally treated for 10 hours with a mock preparation or
15,000 units of IFN-l3 before infection with 100 pfu (,20 LD50)o f
THOV.
doi:10.1371/journal.ppat.1000151.g002
Figure 3. IFN-l activates Mx1 gene expression in lung but not
liver of IFNAR1
0/0 mice. (A) Western blot analysis of Mx1 protein
levels in lungs of mice at 20 hours post intranasal application of 3,500
units of IFN-l3. Animals treated with a mock preparation served as
control. Two animals of each group are shown. (B) Mx1 protein levels in
the liver of IFNAR1
0/0 mice at 20 hours post intraperitoneal application
of 15,000 units of IFN-l3 or terminally ill at 72 hours post infection with
hepatotropic THOV-DML or RVFV clone 13. Two animals for each group
are shown. Liver extract from a wild-type mouse killed at 20 hours post
intraperitoneal treatment with 100,000 units of human IFN-aB/D served
as positive control.
doi:10.1371/journal.ppat.1000151.g003
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6 pfu of SC35M-DNS1 (data
not shown). In marked contrast, all IFNAR1
0/0IL28Ra
0/0 double-
knockout mice infected with 10
5 pfu of SC35M-DNS1 developed
severe disease and had to be killed around day 5 post infection
(Fig. 5A). Additional experiments in which we used lower doses of
challenge virus demonstrated that the LD50 of SC35M-DNS1 in
IFNAR1
0/0IL28Ra
0/0 double-knockout mice was approximately 10
3
pfu (Fig. 5A). A similar picture emerged when the mice were
challenged with a NS1-deficient variant of the H1N1 human
influenza A virus strain PR8 (PR8-DNS1). At a dose of 10
6 pfu, all
infected IFNAR1
0/0IL28Ra
0/0 double-knockout mice developed
severe pneumonia within 4–6 days post infection, whereas all
IFNAR1
0/0 single-knockout mice remained healthy (Fig. 5B).
Importantly, our single- and double-knockout mice did not differ
in susceptibility to infection with the two hepatotropic viruses
THOV-DML (Fig. 5C) and RVFV clone 13 (Fig. 5D), strongly
supporting the above-formulated conclusion that IFN-l is not active
in the liver of IFNAR1
0/0 mice.
High virus load in lungs of mice correlates with low Mx1
protein levels
Virus replication in lungs of wild-type and mutant mice was
assessed at 48 hours post infection with 10
5 pfu of SC35M-DNS1.
Virus titers in lungs of wild-type mice were below the detection
limit in four of five animals, and they were only slightly above the
detection limit in lungs of IL28Ra
0/0 mice at 48 h post infection
(Fig. 6A). Remarkably, SC35M-DNS1 did not grow much better
in lungs of IFNAR1
0/0 mice, whereas it replicated to very high
titers in lungs of IFNAR1
0/0IL28Ra
0/0 double-knockout mice
(Fig. 6A). At 20 hours post infection with SC35M-DNS1 the Mx1
protein levels in lungs of IL28Ra
0/0 mice were about 2-fold lower
than in the wild-type animals (Fig. 6B). Lungs of infected
IFNAR1
0/0 mice contained about 10-fold lower levels of Mx1
protein than wild-type mice, whereas Mx1 levels were below the
detection limit in IFNAR1
0/0IL28Ra
0/0 double-knockout mice
(Fig. 6B). Thus, after infection with SC35M-DNS1, the extent of
Mx1 gene expression in lungs of mice with defective receptors for
IFN-a/b, IFN-l or both correlated inversely with virus titers.
Discussion
The intracellular signaling pathways activated by IFN-l and
IFN-a/b are quite similar [9,10], suggesting that both IFN types
are contributing to virus resistance. Surprisingly, however, mice
lacking functional receptors for IFN-l did not differ from wild-
type mice when challenged with a panel of different pathogenic
viruses [14]. A mild deficiency of IFN-l-deficient mice became
only apparent in an experimental setting in which resistance to
herpes simplex virus type 2 was induced by treating the animals
with TLR3 or TLR9 agonists [14]. This phenotype is in marked
contrast to that of mice lacking functional receptors for IFN-a/b
which are highly susceptible to many viruses [15].
We reasoned that the different phenotypes of the knockout mice
might be explained by the different expression patterns of the
receptors for IFN-a/b and IFN-l in the organism. Receptors for
IFN-a/b are rather uniformly expressed on most if not all
nucleated cells [26], whereas receptors for IFN-l are preferentially
expressed on epithelial cells [13]. If our reasoning was correct, one
would predict that the protective effect of IFN-l should be
restricted to organs with a high percentage of cells expressing the
IFN-l receptor and that the protective effect of IFN-l in these
organs might be most obvious when the IFN-a/b system is
defective. In this report we provide evidence that strongly supports
this view.
We observed that intranasal application of IFN-l protected the
mice from lethal challenge with influenza A virus, whereas
systemic application of IFN-l failed to mediate protection from
disease induced by a hepatotropic virus (Fig. 2). It should be noted
that the mice employed here lacked functional IFN-a/b receptors,
excluding the possibility that the protective effect in the lung was
indirect and resulted from IFN-a/b that might have been induced
by undefined contaminating substances in our IFN-l preparations.
Protection against influenza virus correlated with the presence of
the IFN-induced Mx1 protein in the lung tissue (Fig. 3), suggesting
that lung epithelial cells carry functional IFN-l receptors. By
contrast, no Mx1 protein was found in liver tissue of mice treated
with IFN-l (Fig. 3). The liver tissue also failed to respond to IFN-l
synthesized in the virus-infected liver (Fig. 1), suggesting that
mouse liver cells do not express functional receptors for IFN-l.
This latter conclusion is in agreement with results from recent
quantitative RT-PCR analyses which showed that the alpha chain
of the IFN-l receptor (IL28R-a) is expressed only at very low
levels in liver of mice [13]. However, our results appear to be in
Figure 4. Mice lacking functional receptors for IFN-l show
slightly reduced resistance to influenza A virus. Wild-type and
IL28Ra
0/0 mice were infected by the intranasal route with 5610
4 pfu of
SC35M. (A) Survival and (B) virus titers in lungs at 72 hours post
infection were recorded. Combined data of several independent
experiments are shown. (**: p,0.01).
doi:10.1371/journal.ppat.1000151.g004
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used to inhibit hepatitis B virus replication in a murine hepatocyte
cell line expressing the viral genome as a transgene [27]. However,
these authors observed no induction of IFN-responsive genes in
the liver of mice treated with large amounts of IFN-l, and they
observed no inhibition of hepatitis B virus replication in vivo [27].
In this respect, hepatocyte cell lines may not mirror the normal
behavior of hepatocytes in intact liver tissue.
Since the virus challenge studies in a former report [14] were
carried out with IFN-l receptor knockout mice lacking the IFN-
induced influenza virus resistance factor Mx1, it remained possible
that the beneficial effect of IFN-l against influenza virus had
previously been underestimated. Yet, our new experiments with
Mx1-positive mice revealed that the lack of IFN-l system has
indeed a much less drastic effect on virus resistance than the lack of
the IFN-a/b system. The protective role of IFN-l became only
apparent in Mx1-positive mice that lack a functional IFN-a/b
system, and it was most prominent if influenza virus mutants with
high IFN-inducing potential were used (Fig. 5). It is well known
that highly pathogenic influenza viruses are not controlled well by
the IFN system because the virus-encoded NS1 protein counter-
acts efficient activation of IFN genes in infected cells [21]. NS1-
deficient influenza viruses which are very potent IFN inducers are
highly attenuated in wild-type mice but remain virulent in mice
lacking STAT-1 [21], a transcription factor centrally placed in the
signaling pathways of all IFN types [28]. We found that mutants of
the influenza virus strains SC35M and PR8 lacking NS1 were
completely non-virulent in IFN-a/b receptor-deficient mice and
failed to replicate efficiently in the lung of such mice (Figs 5A and
5B), which should not be the case if IFN-a/b was the only IFN
subtype that confers resistance to influenza viruses. Our
observation that double knockout mice lacking functional
receptors for IFN-a/b and IFN-l are highly susceptible to the
NS1-deficient influenza virus mutants clearly demonstrates that
IFN-l provides the residual protection in IFN-a/b receptor-
deficient mice.
Some important conclusions can be drawn from our data
regarding the role of different IFN types in antiviral immunity.
Figure 5. Mice lacking functional receptors for both IFN-a/b and IFN-l exhibit enhanced susceptibility toward highly attenuated
influenza A viruses but not toward two different attenuated hepatotropic viruses. Survival of IFNAR1
0/0 (diamonds) and IFNAR1
0/0IL28Ra
0/0
double knockout mice (circles) after (A) intranasal infection with the indicated doses of SC35M-DNS1, (B) intranasal infection with 10
6 pfu of PR8-
DNS1, (C) intraperitoneal infection with the indicated doses of THOV-DML, and (D) intraperitoneal infection with the indicated doses of RVFV clone
13. Groups consisted of four to nine animals.
doi:10.1371/journal.ppat.1000151.g005
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on the IFN-a/b system. Our data clearly demonstrate that the
IFN-l system also contributes to innate immunity against
influenza A virus. The second important conclusion from our
study is that the IFN-a/b system is dominant over the IFN-l
system. IFN-l thus appears to be part of a secondary defense
system which can fill gaps left by the IFN-a/b system. Future
studies will help to distinguish between the possibility that IFN-l is
predominantly active against influenza viruses and the possibility
that IFN-l plays a broader role in the lung and improves innate
immunity against other pathogenic viruses that infect the
respiratory tract. Evidence in favor of the second possibility
includes the observation that IFN-l also restricted vaccinia virus
replication in the lung of mice [29]. We further noted with interest
that, reminiscent to the situation with NS1-deficient influenza
virus, IFN-a/b receptor-deficient mice are able to restrict the
growth of human respiratory syncytial virus in the lung far better
than STAT-1-deficient mice [30]. This observation suggests that
IFN-l might also help controlling respiratory syncytial virus. Since
receptors for IFN-l are expressed on epithelial cells of many
different organs including lung, stomach and intestine [13], it is
conceivable that the physiological role of this cytokine is to protect
the host from viral infections via mucosal membranes at many
different body sites. An important issue to be addressed in the
future is whether IFN-l might serve a similar role in humans.
Materials and Methods
Mice
All animals used were of C57BL/6 genetic background.
Congenic B6.A2G-Mx1 mice [31] carrying intact Mx1 alleles
and B6.A2G-Mx1-IFNAR1
0/0 mice lacking functional type I IFN
receptors [19] were bred locally. C57BL/6 mice lacking functional
type III IFN receptors (IL28Ra
0/0) [14] were crossed with
B6.A2G-Mx1 and B6.A2G-Mx1-IFNAR1
0/0 mice to produce
strains with intact Mx1 alleles and defective alleles for IL28Ra
only, or IL28Ra and IFNAR1 in combination. Six- to eight-week-
old animals were used for all infection experiments, which were
performed in accordance with the guidelines of the local animal
care committee. Animals were euthanized if severe symptoms
developed or body weight loss approached 30% of the initial value.
Viruses
We used wild-type influenza A virus strains SC35M (H7N7) and
A/PR/8/34 (H1N1) as well as mutants SC35M-DNS1 [22] and
PR8-DNS1 [21] lacking the IFN-antagonistic factor NS1. We
further used wild-type Thogotovirus (THOV) or mutant THOV-
DML lacking the IFN-antagonistic factor ML [23], and the
attenuated ‘‘clone 13’’ strain of Rift Valley fever virus (RVFV)
lacking functional IFN-antagonistic factor NSs [25]. All these
viruses are classified as BSL2 pathogens in Germany.
Virus infections
Animals were anesthetized by intraperitoneal injection of a
mixture of ketamine (100 mg per gram body weight) and xylazine
(5 mg per gram body weight) before intranasal infection with the
indicated doses of the various influenza A viruses in 50 ml PBS
containing 0.3% BSA. For THOV and RVFV infections, 100 ml-
samples of diluted virus stocks were applied intraperitoneally
without anaesthesia.
Cytokines
IFN-l2 and IFN-l3 were produced by transient transfection of
293T cells with appropriate expression plasmids [9]. The
biological activity of IFN-l2 and IFN-l3 was determined as
previously described [32]. Hybrid human IFN-aB/D that is highly
active on mouse cells was used as positive control [17,33].
IFN treatment of mice
Samples containing the indicated amounts of IFN-l2 or IFN-l3
were either applied intranasally (50 ml) to anesthetized animals or
injected intraperitoneally (200–300 ml) without anaesthesia.
Titration of virus in lungs
Lung homogenates were prepared by grinding the tissue using a
mortar and sterile quartz sand. Homogenates were suspended in
1 ml of PBS, and tissue debris was removed by low speed
centrifugation. Virus titers in supernatants were determined by
performing plaque assays on MDCK II cells by serial 10-fold
dilutions in PBS containing 0.3% BSA.
RT-PCR
Lung and liver were removed, and frozen immediately in liquid
nitrogen. RNA was isolated from the organs using 1 ml of TriFast
according to the protocol of the manufacturer (peQLab). The
RNA was further purified by using RNeasy mini kit columns
(Qiagen). One mg of each RNA preparation was reverse-
transcribed using random-hexamer primers and reverse transcrip-
tase. The reaction products were used to amplify the cDNAs by
Figure 6. Inverse correlation of Mx1 protein levels and viral
load in lungs of mice lacking functional receptors for IFN-a/b,
IFN-l or both. Groups of mice were infected with 10
5 pfu of SC35M-
DNS1 and either killed at (A) 48 hours post infection to determine viral
titers in the lung or at (B) 20 hours post infection to determine Mx1
protein levels by western blotting. Two animals of each group are
shown. Actin-normalized Mx1 signal intensities are indicated. The
calculated value of the wild-type mice was set to 100%. (*: p,0.05), ***:
p,0.001).
doi:10.1371/journal.ppat.1000151.g006
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mouse IFN-b (accession no. NM_010510, primers from positions
21–42 and 145–124), the mouse IFN-a family (accession
no. NM_010504, primers from positions 46–68 and 557–534),
mouse IFN-l2 (accession no. NM_001024673, primers from
positions 83–104 and 191–170), and mouse b-actin (accession
no. X03672, primers from positions 1374–1396 and 1585–1564).
RT-PCR products were separated by agarose electrophoresis,
stained with ethidium bromide and visualized under UV light.
Western blot analysis
Lung homogenates were prepared by grinding the tissue using a
mortar and sterile quartz sand. Homogenates were lysed in buffer
containing 50 mM Hepes (pH 7.3), 125 mM NaCl, 1% Nonidet
P-40, 1 mM EDTA, 0.5% sodium deoxycholate, 0.1% SDS,
1 mM DTT, 100 units/ml of benzonase, and protease inhibitors
as recommended by the manufacturer (Roche). Lysates were
subjected to low speed centrifugation, and supernatants were
diluted with concentrated gel loading buffer containing b-
mercaptoethanol. Proteins were separated by SDS-polyacrylamide
gel electrophoresis (10% gel) and transferred onto polyvinyliden-
fluoride membranes (Millipore). The blots were probed with
monoclonal mouse antibody specific for Mx1 [34] and monoclonal
mouse antibody against actin (Sigma). Horseradish peroxidase-
labeled secondary antibodies and the chemoluminescence detec-
tion system (Pierce) were used to detect primary antibodies. Signal
quantification was done with a ChemiDoc XRS equipment
(BioRad).
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